Theresa A O'Keefe from West Roxbury, MA, age 62

Senior Scientist

view source

Location:

20 Richgrain Ave, Waltham, MA 02453

Industry:

Biotechnology

Work:

Chiesi Usa, Inc.
Senior Scientist

Associate Professor Of The Practice , School Of Theology And Ministry

view source

Location:

11 Vinal St, Brighton, MA 02135

Industry:

Higher Education

Work:

Boston College since Sep 2005
Assistant Professor, School of Theology and Ministry
Boston College - Boston since Sep 2005
Director of Contextual Education, School of Theology and Ministry
Roman Catholic Diocese of Springfield MA 1990 - 2000
Consultant on Religious Education

Education:

Boston College 2000 - 2006
PhD, Theology & Education Boston College 1988 - 1990
MEd, Religious Education University of Toronto - University of St. Michael's College 1981 - 1985
BA, Religious Studies

Skills:

Teaching
Theology
Curriculum Development
Leadership
Student Development
Higher Education
Religion
Public Speaking
Social Justice
Nonprofits
Youth Ministry
Youth Development
Religious Studies
Program Development
Academic Writing
Student Affairs
Adult Education
Practical Theology
Supervising
Supervisory Training
Student Advising
Pastoral Theology
Young Adult Ministry

Theresa O'keefe

view source

Theresa O'keefe

view source

Us Patents

Monoclonal Antibodies Against Hmgb1
view source
US Patent:

7288250, Oct 30, 2007
Filed:

Sep 10, 2004
Appl. No.:

10/938992
Inventors:

Walter Newman - Boston MA, US
Shixin Qin - Lexington MA, US
Theresa L. O'Keefe - Waltham MA, US
Robert A. Obar - Walpole MA, US
Assignee:

Critical Therapeutics, Inc. - Lexington MA
International Classification:

A61K 39/395
C07K 16/24
US Classification:

4241331, 4241451, 435810, 435335, 435355, 5303873, 5303881, 53038823
Abstract:

In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.

Humanized Anti-Ccr2 Antibodies And Methods Of Use Therefor
view source
US Patent:

7442775, Oct 28, 2008
Filed:

Jan 27, 2004
Appl. No.:

10/766610
Inventors:

Gregory J. LaRosa - Newton MA, US
Christopher Horvath - Taunton MA, US
Walter Newman - Boston MA, US
S. Tarran Jones - Radlett, GB
Siobhan H. O'Brien - London, GB
Theresa O'Keefe - Waltham MA, US
Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA
International Classification:

C07H 23/00
A61K 39/00
C12N 15/00
US Classification:

5303879, 536 2353, 4353201, 435328
Abstract:

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e. g. , human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.

Rage Protein Derivatives
view source
US Patent:

7470521, Dec 30, 2008
Filed:

Jul 20, 2005
Appl. No.:

11/186422
Inventors:

Theresa O'Keefe - Waltham MA, US
Peter Luciano - Maynard MA, US
Shixin Qin - Lexington MA, US
Assignee:

Critical Therapeutics, Inc. - Lexington MA
International Classification:

C12P 21/06
A61K 39/00
C07H 21/04
C12P 21/04
C12N 5/00
C12N 5/16
C12N 15/64
C12N 1/20
US Classification:

435 691, 4241921, 536 234, 435 697, 435325, 4353441, 435 914, 4352523
Abstract:

The present invention is drawn to fusion proteins comprising a Receptor for Advanced Glycation Endproducts (RAGE) and an immunoglobulin element. The invention also encompasses methods of treating a condition characterized by activation of an inflammatory cytokine cascade comprising administering such fusion proteins. The invention is also drawn to nucleic acids encoding the fusion proteins, as well as vectors and cells comprising such nucleic acids.

Humanized Anti-Ccr2 Antibodies And Methods Of Use Therefor
view source
US Patent:

7473421, Jan 6, 2009
Filed:

Jan 27, 2004
Appl. No.:

10/766773
Inventors:

Gregory J. LaRosa - Newton MA, US
Christopher Horvath - Taunton MA, US
Walter Newman - Boston MA, US
S. Tarran Jones - Radlett, GB
Siobhan H. O'Brien - London, GB
Theresa O'Keefe - Waltham MA, US
Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA
International Classification:

C07K 16/00
A61K 39/02
US Classification:

4241391, 435 696, 435 5
Abstract:

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e. g. , human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.

Humanized Anti-Ccr2 Antibodies And Methods Of Use Therefor
view source
US Patent:

7566450, Jul 28, 2009
Filed:

Oct 26, 2007
Appl. No.:

11/924794
Inventors:

Gregory J. LaRosa - Newton MA, US
Christopher J. Horvath - Taunton MA, US
Walter Newman - Boston MA, US
S. Tarran Jones - Hertfordshire, GB
Siobhan H. O'Brien - London, GB
Theresa O'Keefe - Waltham MA, US
Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA
International Classification:

A61K 39/395
US Classification:

4241391, 4241421, 4241431
Abstract:

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e. g. , human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.

Monoclonal Antibodies Against Hmgb1
view source
US Patent:

7632500, Dec 15, 2009
Filed:

Sep 20, 2007
Appl. No.:

11/903129
Inventors:

Walter Newman - Boston MA, US
Shixin Qin - Lexington MA, US
Theresa L. O'Keefe - Waltham MA, US
Robert A. Obar - Walpole MA, US
Assignee:

Cornerstone Therapeutics, Inc. - Cary NC
International Classification:

A61K 39/395
C07K 16/24
US Classification:

4241341, 4241451, 435810, 5303873
Abstract:

In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.

Humanized Anti-Ccr2 Antibodies And Methods Of Use Therefor
view source
US Patent:

8227211, Jul 24, 2012
Filed:

Sep 23, 2008
Appl. No.:

12/235765
Inventors:

Gregory J. LaRosa - Newton MA, US
Christopher Horvath - Taunton MA, US
Walter Newman - Boston MA, US
S. Tarran Jones - Hertfordshire, GB
Siobhan H. O'Brien - Herts, GB
Theresa O'Keefe - Waltham MA, US
Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA
International Classification:

A61K 39/395
C12N 15/13
C07K 16/00
US Classification:

435 696, 43525231, 43525233, 43525411, 435375, 4241331, 5303873
Abstract:

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e. g. , human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.

Hybrid Antibodies And Uses Thereof
view source
US Patent:

20020147312, Oct 10, 2002
Filed:

Jan 30, 2002
Appl. No.:

10/060714
Inventors:

Theresa O'Keefe - Waltham MA, US
Patricia Rao - Acton MA, US
International Classification:

C07K016/28
US Classification:

530/387300, 530/388150
Abstract:

Methods of providing hybrid antibodies having improved assembly characteristics are disclosed. Accordingly, the present invention provides hybrid antibodies, antigen binding fragments thereof, which include a chimeric immunoglobulin heavy chain and a humanized or CDR-grafted immunoglobulin light chain, pharmaceutical compositions thereof, as well as nucleic acids encoding the aforesaid antibodies, host cells and vectors containing such nucleic acids. Therapeutic and diagnostic uses of such hybrid antibodies molecules thereof are also disclosed.